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Abstract: Triple-negative breast cancer (TNBC) is known to have a poor prognosis and
limited treatment options, namely chemotherapy. Different molecular studies have recently
classified TNBC into different subtypes opening the door to potential new-targeted treatment
options. In this review, we discuss the current standard of care in the treatment of TNBC in
the neoadjuvant, adjuvant and metastatic settings. In addition, we summarize the ongoing
phase III clinical trials evaluating different associations between the 3 pillars of anticancer
treatment: chemotherapy, targeted therapy and immunotherapy.
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Introduction
Breast cancer continues to be the second cause of death in women worldwide.1
Triple-negative breast cancer (TNBC) is defined by the lack of expression of
estrogen (ER), progesterone (PR) and HER2 receptors. TNBC represents approxi-
mately 10–15% of all diagnosed breast cancers.2 The pattern of metastatic spread in
TNBC is different from the other breast cancer subtypes with a higher likelihood of
brain and lung involvement and less frequent bone lesions; in addition, this is the
tumor subtype with the poorest prognosis between all breast cancer subtypes.3
In the current era, more in-depth studies have divided TNBC into different
subtypes, according to their molecular characteristics. By analyzing gene-expres-
sion profile of TNBC, Lehman et al showed the existence of 6 different subtypes:
basal-like 1 and 2, immunomodulatory, mesenchymal, mesenchymal stem-like and
luminal androgen receptors.4 In a more recent study, the same authors re-classified
these tumors into 4 groups: basal-like 1, basal-like 2, mesenchymal and luminal
androgen receptor.5 Another classification for TNBC was suggested by Burstein et
al describing four subtypes: luminal androgen receptor, mesenchymal, basal-like
immune-suppressed and basal-like immune-activated.6 In the same study, the basal-
like immune-activated subtype showed to be associated with good prognosis, which
is compatible with the results of other studies showing better outcomes for TNBC
having lymphocytic infiltration.7,8
TNBC is more often associated with hereditary conditions as compared to other
breast cancer subtypes. For instance, among newly diagnosed breast cancer
patients, <10% have BRCA1 or BRCA2 mutated genes but this percentage is higher
among patients with TNBC with around 35% of BRCA1 and 8% of BRCA2
mutations in this population. Among BRCA1 mutation carriers, more than one-
third have TNBC.9 TNBC diagnosed in women at the age of 60 years or less is
Correspondence: Matteo Lambertini
IRCCS Ospedale Policlinico San Martino,
University of Genova, Largo Rosanna
Benzi 10 16132, Genova, Italy
Tel +39 010 555 4254
Fax +39 010 555 6536
Email matteo.lambertini@unige.it
International Journal of Women's Health Dovepress
open access to scientific and medical research
Open Access Full Text Article
submit your manuscript | www.dovepress.com International Journal of Women's Health 2019:11 431–437 431
DovePress © 2019 Mehanna et al. This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.
php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the
work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For
permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).
http://doi.org/10.2147/IJWH.S178349
considered a criterion to test for BRCA mutations.9 Tumors
missing the germline mutations in BRCA1/2 but keeping
the same characteristics are classified as “BRCAness.”10
In this review, we discuss the standard of care in the
treatment of TNBC in the neoadjuvant, adjuvant and meta-
static settings. In addition, we summarize the ongoing
phase III clinical trials evaluating different associations
between the 3 pillars of anticancer treatments: chemother-
apy, targeted therapy and immunotherapy.
Different subtypes of TNBC
Basal-like 1 and 2 subtypes
It is estimated that 75% of TNBC belong to the basal-like
subtypes, and TNBC forms the largest part of the basal-
like subtypes11 (Figure 1).
Basal-like 1 is associated with an elevated DNA
damage response and Ki67 levels.4 Burstein et al showed
that basal-like immune-suppressed subtypes of TNBC
have downregulation of B cell, T cell and natural killer
in both cytokines and immune pathways, which results in
worse prognosis for these subtypes.6 Mostly, all cell lines
harboring mutations in BRCA1 and BRCA2 have correla-
tion with the gene patterns of the basal-like subtype.12
Luminal androgen receptor subtype
The luminal androgen receptor subtype contains pathways
that regulate steroid synthesis, porphyrin metabolism and
androgen/estrogen metabolism.6 In this subtype, the andro-
gen receptor is heavily expressed, with an expression 10-
fold greater than the other subtypes.4
Mesenchymal and mesenchymal stem-like
subtypes
In addition to the mesenchymal subtypes having pathways
included in the motility and cell differentiation, the
mesenchymal stem-like subtype is characterized by having
components interfering with the EGFR, calcium signaling,
G-protein receptors.11
Immunomodulatory subtype
In the classification of Burstein et al,6 immunomodula-
tory subtype is considered as another type of basal-like
subtype, ie, the basal-like immune-activated subtype. It
has a favorable prognosis. It is characterized by an
upregulation in genes responsible for T-cell, B-cell
and natural killer, by having a high expression of
STAT genes.
Standard of care in TNBC
The standard of care in patients with TNBC defined by the
guidelines of the European Society of Medical Oncology
(ESMO) and the American Society of Clinical Oncology
(ASCO) is reported in this section.
Neoadjuvant treatment
The addition of carboplatin in the neoadjuvant setting
showed to increase the rate of pathological complete
response in TNBC from 37.0% to 52.1% (OR 1.96, 95%
CI 1.46–2.62). Consequently, it can be considered a pos-
sible option in patients with TNBC at the cost of more
frequent hematological toxicities.13
For patients with TNBC treated in the neoadjuvant
setting but with residual disease post-chemotherapy at
the time of surgery, the CREATE-X trial demonstrated
improved outcomes when administering capecitabine for
six to eight cycles as adjuvant treatment. Disease-free
survival rate at 5 years was improved with capecitabine
by around 14% (69.8% vs 56.1%; HR 0.58; 95% CI 0.39–
0.87) and overall survival (OS) at 5 years was improved
by around 8% (78.8% vs 70.3%; HR 0.52; 95% CI 0.30–
0.90).14 The post-neoadjuvant setting has gained great
attention after the publication of the CREATE-X trial and
several studies are currently investigating new treatment
options for patients with residual disease at the time of
surgery.15
Adjuvant treatment
The vast majority of TNBC benefit from adjuvant che-
motherapy with the possible exception of some low-risk
histologic subtypes (secretory juvenile, apocrine, or ade-
noid cystic carcinomas). When adjuvant chemotherapy is
indicated, anthracycline- and taxane-based regimens are
considered the optimal strategy.16
20 to 30% are
not basal-like





Figure 1 Basal-like subtype and triple-negative breast cancer.
Mehanna et al Dovepress
submit your manuscript | www.dovepress.com
DovePress
International Journal of Women's Health 2019:11432
Dose-dense chemotherapy is of special interest in these
aggressive tumors. In fact, efficacy may be enhanced when
increasing the intensity of treatment by giving individual
drugs sequentially at full dose rather than in lower-dose
concurrently, or by shortening the intervals between
cycles. This was evaluated in an individual patient-level
meta-analysis of trials comparing 2-weekly versus stan-
dard 3-weekly schedules and of trials comparing sequen-
tial versus concurrent administration of anthracycline and
taxane chemotherapy. Data were provided for 26 trials
including 37,298 patients, most aged younger than 70
years. It showed that fewer breast cancer recurrences
were seen with dose-intense than with standard-schedule
chemotherapy (10-year recurrence 28.0% vs 31.4%; RR
0.86; 95% CI 0.82–0.89). Similarly, 10-year breast cancer
mortality was reduced (18.9% vs 21.3%; RR 0.87, 95% CI
0.83–0.92), as was all-cause mortality (22.1% vs 24.8%;
RR 0.87, 95% CI 0.83–0.91).17
The role of platinum agents in the early setting is
currently being evaluated. The US trial EA1131 is an
ongoing randomized phase III post-operative trial compar-
ing single-agent platinum-based chemotherapy to capeci-
tabine in patients with residual TNBC with residual
disease after standard neoadjuvant chemotherapy. The pri-
mary objective consists in comparing the invasive disease-
free survival.18
Treatment of advanced disease
Chemotherapy
In patients with advanced TNBC treated with an anthracy-
cline with or without a taxane in the neoadjuvant or adju-
vant setting, carboplatin demonstrated comparable efficacy
and a more favorable toxicity profile than docetaxel.19 In
the subgroup of patients with germline BRCA1/2-mutated
breast cancer, carboplatin showed to double the objective
response rate as compared to docetaxel (68% vs 33%,
P=0.01).19 This suggests the importance of characterizing
the BRCA1/2 mutation status of patients with advanced
disease to also help informing on the choices of the best
first-line chemotherapy approach.
Poly ADP-ribose polymerase (PARP) inhibitors
Olaparib FDA- and EMA-approved targeted therapy
In metastatic patients harboring a germline BRCA muta-
tion, olaparib has shown important activity in both TNBC
and luminal-like disease.20–22 The OlympiAD study was
designed to compare the use of olaparib versus standard
single-agent chemotherapy (capecitabine, eribulin, or
vinorelbine in 21-day cycles) in BRCA-mutated breast
cancer patients. Among the 302 patients that underwent
randomization, 205 received olaparib and 97 received
standard chemotherapy. Response rate was 59.9% in
patients receiving olaparib and 28.8% in patients receiving
standard chemotherapy. The rate of adverse events was
higher (50.6%) in the chemotherapy group versus the
olaparib group (36.6%). Median progression-free survival
(PFS) was 7.0 months with olaparib and 4.2 months with
chemotherapy (HR 0.58; 95% CI 0.43–0.80). However, no
significant difference was observed in OS that was 19.3
months with olaparib and 17.1 months with standard ther-
apy (HR 0.90; 95% CI 0.66–1.23).23,24
Talazoparib FDA-approved targeted therapy
With a similar design as the OlympiAD study, the
EMBRACA trial showed important activity for talazoparib
in the treatment of metastatic breast cancer patients har-
boring a germline BRCA mutation including women with
TNBC.25 This was a randomized open-label phase III
study that included 431 patients divided into two groups:
287 patients received talazoparib and 144 received stan-
dard chemotherapy (capecitabine, eribulin, gemcitabine
and vinorelbine). A significantly longer median PFS, the
primary outcome of the study, was observed with the
group receiving talazoparib (8.6 months vs 5.6 months;
HR 0.54; 95% CI 0.41–0.71). The objective response rate
was also higher in the talazoparib group than in the che-
motherapy group (62.6% vs 27.2%; OR, 5.0; 95% CI, 2.9–
8.8). Median OS was 22.3 months (95% CI 18.1–26.2) in
the talazoparib group and 19.5 months (95% CI 16.3–22.4)
in the chemotherapy group, with no significant difference
(HR 0.76; 95% CI 0.55–1.06).
Respectively, hematologic grades 3–4 adverse events
(primarily anemia) and nonhematologic grade 3 adverse
events occurred in 55% and 32% of the patients who
received talazoparib and each in 38% of the patients who
received standard therapy.
In this trial, quality of life in the two treatment arms
was assessed. In the patient-reported outcomes analysis, a
significant overall improvement was seen in the global
health status/quality of life with the use of talazoparib as
compared to chemotherapy.26
Immunotherapy
Atezolizumab has shown safety and good clinical activity
in TNBC.27 Chemotherapy, taxanes in particular, may
enhance tumor antigens release by activating toll-like
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receptors and promoting dendritic cell activity.28 Based on
this rationale, a phase III trial randomized patients with
metastatic TNBC to first-line atezolizumab plus nab-pacli-
taxel and placebo plus nab-paclitaxel.29 This study had
two primary end points: PFS and OS. A total of 451
patients were included in each treatment group. A better
PFS was obtained in the atezolizumab plus nab-paclitaxel
group (7.2 months vs 5.5 months; HR 0.80; 95% CI 0.69–
0.92). OS with atezolizumab plus nab-paclitaxel was 21.3
months as compared to 17.6 months in the chemotherapy
alone group (HR 0.84; 95% CI 0.69–1.02). A predefined
subgroup analysis showed a greater benefit with the addi-
tion of immunotherapy among patients having PD-L1
positive tumors: median PFS was 7.5 months versus 5.0
months (HR 0.62; 95% CI 0.49–0.78) and median OS was
25.0 months versus 15.5 months (HR 0.62; 95% CI 0.45–
0.86) favoring the group receiving atezolizumab plus nab-
paclitaxel. Recently, the combination of atezolizumab plus
nab-paclitaxel has been approved by FDA as first-line
therapy in patients with PD-L1 positive TNBC.30
The results of several ongoing trials are awaited to
further investigate the role of immunotherapy for the treat-
ment of patients with TNBC in all disease settings
(Table 1).
Promising agents in TNBC
PARP inhibitors beyond olaparib/talazoparib
and the metastatic setting
Several other PARP inhibitors beyond olaparib and tala-
zoparib are currently under investigation for the treat-
ment of patients with BRCA-mutated breast cancer.31
Veliparib has been investigated in breast cancer patients
with metastatic disease in combination with chemother-
apy. A significant anti-tumor effect was shown with the
combination of veliparib plus temozolomide.32 In the
BrighTNess phase III randomized trial, the addition of
veliparib to carboplatin and standard neoadjuvant che-
motherapy did not show any advantage related to patho-
logic complete response compared to carboplatin and
standard chemotherapy.33
To investigate the activity of PARP inhibitors in TNBC
patients, both in the adjuvant and the post-neoadjuvant
settings, the phase III OLYMPIA trial (ClinicalTrials.gov
identifier: NCT02032823) is currently randomizing early
HER2-negative breast cancer patients harboring BRCA
germline mutations to 1 year of olaparib or placebo after
surgery and standard chemotherapy.15
Androgen receptor inhibitors
In a study by Gucalp et al,34 242 patients with TNBC were
tested for androgen receptors, and 12% of them were
found positive. This phase II study used single-agent bica-
lutamide showing a 6-month clinical benefit rate of 19%
(95% CI 7–39%).
Enzalutamide was also studied in a subset of TNBC
tumors with expression of androgen receptors.35 In the
overall population, the study showed a clinical benefit
rate at 16 weeks of 25% (95% CI 17–33%). In a biomarker
exploratory analysis, patients having positive androgen-
driven gene signatures showed greater clinical benefit
rate (39% vs 11%).
Trials are ongoing to assess enzalutamide in this set-
ting. As an example, the NCT02750358 trial is designed to
determine the feasibility of adjuvant enzalutamide for the
treatment of patients with TNBC.
Antibody–drug conjugates
Sacituzumab govitecan is an antibody–drug conjugate in
which SN-38 (an active metabolite of the topoisomerase I
inhibitor, irinotecan) is coupled to a monoclonal antibody
targeting anti-trophoblast cell-surface antigen 2 (Trop-2).36
Trop-2, stimulates cancer-cell growth and is detected in
breast cancer cells, including TNBC.36 This molecule
allows the delivery of the drug to the tumors both intra-
cellularly and in the tumor microenvironment. The safety
and efficacy of this treatment were evaluated in a phase I/
II trial in patients with TNBC that have received a median
of 3 previous therapies.36 Overall response rate was 33.3%
and clinical benefit rate was 45.4%. Median PFS was 5.5
months and median OS was 13.0 months.37
A randomized phase III trial (ASCENT, NCT02574455)
is currently comparing sacituzumab govitecan to standard
chemotherapy in the treatment of patients with metastatic
TNBC with prior exposure to taxane.
Additional therapeutic agents
TNBC is considered having a high prevalence of PI3K/
AKT pathway activation.38 The LOTUS trial was a rando-
mized phase II trial that investigated the addition of ipa-
tasertib (an orally administered, ATP-competitive,
selective AKT inhibitor) to paclitaxel as first-line
treatment.39 Patients were randomized to ipatasertib and
paclitaxel vs paclitaxel and placebo. Median PFS was 6.2
months in the group receiving ipatasertib vs 4.9 months in
the group receiving paclitaxel and placebo (HR 0.60; 95%
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CI 0.37–0.98). Further investigations are ongoing in the
NCT03337724 phase III trial evaluating the efficacity of
ipatasertib with paclitaxel versus paclitaxel and placebo in
450 participants.
AZD5363 is a highly selective, oral, small molecule
AKT inhibitor, that is being investigated in addition to
paclitaxel as first-line therapy for TNBC. Results pre-
sented at ASCO 2018 showed that the combination
resulted in a significantly longer PFS with a median PFS
of 5.9 compared to 4.2 months, and longer OS with a
median OS of 19.1 vs 12.6 months (HR 0.64; 95% CI
0.40–1.01). AZD5363 warrants further investigation for
the treatment of TNBC.40
Conclusion
TNBC is a heterogeneous disease characterized by many
subtypes that differ in natural history and may be candidates
to different treatment options. Besides standard anthracy-
cline- and taxane-based chemotherapy, recent studies have
better elucidated the potential role of platinum agents in
both the neoadjuvant and metastatic settings. In patients
with germline BRCA mutations, PARP inhibitors have
proved to be effective treatment options in the metastatic
setting and are currently being explored in the early setting.
Immunotherapy also proved to be effective and has recently
become a standard of care in metastatic breast cancer.
Several new promising treatment options are under
active evaluation in many clinical trials. Among them,
the most promising strategies include androgen receptor-
inhibitors, antibody–drug conjugate (eg, sacituzumab
govitecan) and AKT inhibitors.
After many years without breakthroughs in the field of
TNBC and with chemotherapy remaining the only treat-
ment option in this setting, several promising agents are
becoming available or are in late stage of clinical devel-
opment giving hope for a more personalized therapy also
in patients with this breast cancer subtype.
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